Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers

被引:5
作者
Bendandi, M
Tonelli, R
Maffei, R
Botti, S
Turi, C
Sartini, R
Inogés, S
Calvillo, MR
Zinzani, PL
Pession, A
Pileri, SA
Paolucci, G
机构
[1] Univ Navarra, Dept Hematol, Clin Univ, Pamplona 31008, Spain
[2] Univ Bologna, Dept Pediat, I-40126 Bologna, Italy
[3] Univ Bologna, Inst Hematol & Med Oncol Seragnoli, I-40126 Bologna, Italy
关键词
CDR3; consensus primers; follicular lymphoma; PCR; tumor-specific;
D O I
10.1023/A:1012586905273
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The complementarity determining region 3 (CDR3) of the immunoglobulin (Ig) heavy chain variable region (V-H) is the most reliable molecular fingerprint for most if not all human B cells. The nucleotide sequence encoding for any B-cell tumor-specific V-H CDR3 is currently identified by PCR sequencing based on procedures involving the usage of either radioactive materials, patient/family-specific primers, or bacterial cloning. Patients and methods: In six consecutive patients with follicular lymphoma we assessed the feasibility of a method that allows for identification of the tumor-specific V-H CDR3 using consensus primers while avoiding both radioactive materials and bacterial cloning procedures. Results: The tumor-specific V-H CDR3 was successfully identified in all six patients in nearly half the time typically required by any other method currently utilized. The feasibility of the proposed method was not significantly affected either by the tumor-specific Ig isotype, or by the tumor infiltration in the original biopsy specimen. In the three patients for whom tumor specimen-derived hybridomas were available, the tumor-specific V-H CDR3 was also found in at least 8 of 10 of them. Conclusions: The proposed method allows the ability to quickly identify the B-cell tumor-specific V-H CDR3 using consensus primers while avoiding radioactive materials and bacterial cloning procedures.
引用
收藏
页码:1479 / 1484
页数:6
相关论文
共 21 条
[1]   Anti-idiotype vaccines for human follicular lymphoma [J].
Bendandi, M .
LEUKEMIA, 2000, 14 (08) :1333-1339
[2]   Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma [J].
Bendandi, M ;
Gocke, CD ;
Kobrin, CB ;
Benko, FA ;
Sternas, LA ;
Pennington, R ;
Watson, TM ;
Reynolds, CW ;
Gause, BL ;
Duffey, PL ;
Jaffe, ES ;
Creekmore, SP ;
Longo, DL ;
Kwak, LW .
NATURE MEDICINE, 1999, 5 (10) :1171-1177
[3]   MOUSE X HUMAN HETEROHYBRIDOMAS AS FUSION PARTNERS WITH HUMAN B-CELL TUMORS [J].
CARROLL, WL ;
THIELEMANS, K ;
DILLEY, J ;
LEVY, R .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 89 (01) :61-72
[4]   Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulations [J].
Caspar, CB ;
Levy, S ;
Levy, R .
BLOOD, 1997, 90 (09) :3699-3706
[5]   Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma [J].
Cavo, M ;
Terragna, C ;
Martinelli, G ;
Ronconi, S ;
Zamagni, E ;
Tosi, P ;
Lemoli, RM ;
Benni, M ;
Pagliani, G ;
Bandini, G ;
Tura, S .
BLOOD, 2000, 96 (01) :355-+
[6]   Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone [J].
Davis, TA ;
Maloney, DG ;
Czerwinski, DK ;
Liles, TM ;
Levy, R .
BLOOD, 1998, 92 (04) :1184-1190
[7]  
HARRIS NL, 1994, BLOOD, V84, P1361
[8]  
HAWKINS RE, 1994, BLOOD, V83, P3279
[9]   Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long-term results of a clinical trial [J].
Hsu, FJ ;
Caspar, CB ;
Czerwinski, D ;
Kwak, LW ;
Liles, TM ;
Syrengelas, A ;
TaidiLaskowski, B ;
Levy, R .
BLOOD, 1997, 89 (09) :3129-3135
[10]   PREFERENTIAL USE OF THE VH4 IG GENE FAMILY BY DIFFUSE LARGE-CELL LYMPHOMA [J].
HSU, FJ ;
LEVY, R .
BLOOD, 1995, 86 (08) :3072-3082